High-dose IgG for neutropenic patients with acquired immunodeficiency syndrome (AIDS). NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


High-dose IgG for neutropenic patients with acquired immunodeficiency syndrome (AIDS).

Ann Hematol. 1991 Aug;63(2):77-8. Unique Identifier : AIDSLINE MED/92002438
Salama A; Lohmeyer J; Seeger W; Mueller-Eckhardt C; Department of Internal Medicine, Justus Liebig University; Giessen, Federal Republic of Germany.

Abstract: Leukocytopenia and bacterial infections are common and serious complications in patients with AIDS. We report here on three patients in whom the administration of high IgG doses led to gradual (two patients) or prompt (one patient) increases in circulating leukocyte counts (from 200-600 to 2500-5900/microliters), inducing definite improvement in two patients; one patient died from Pneumocystis carinii pneumonia. Although the rise in leukocyte counts lasted for only approximately 3 weeks, high-dose IgG might be a useful therapeutic adjunct in such patients.
Keywords: Acquired Immunodeficiency Syndrome/*BLOOD/DRUG THERAPY Anemia/CHEMICALLY INDUCED Hematopoiesis/DRUG EFFECTS Human IgG/*ADMINISTRATION & DOSAGE/THERAPEUTIC USE Neutropenia/*DRUG THERAPY Support, Non-U.S. Gov't Thrombocytopenia/CHEMICALLY INDUCED Zidovudine/ADVERSE EFFECTS/THERAPEUTIC USE JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/KWDblood/drugtherapyanemia/chemicallyinducedhematopoiesis/drugeffectshumanigg/KWDadministration&dosage/therapeuticuseneutropenia/KWDdrugtherapysupport,non-uKWDsKWDgov'tthrombocytopenia/chemicallyinducedzidovudine/adverseeffects/therapeuticusejournalarticle
920130
M9210710

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .